secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2025-03-28T23:59:59+00:00
Accession:  0001193125-25-067071
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya Therapeutics approves restructuring; workforce reduction extends cash runway to H2 2026
--------------------------------------------------------------------------------

- Restructuring focuses resources on TN-201 (MyPEAK-1) and TN-401 (RIDGE-1) gene therapy trials.
- Workforce reduction implemented; no expected impact on enrollment milestones or data readouts.
- Estimated severance and health benefit charges of $1.6M–$2.7M, substantially all by Q3 2025.
- Cash runway extended into second half of 2026 via cost-containment measures.
- Sufficient drug product produced for ongoing trials; manufacturing for pivotal studies continues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000119312525067071/0001193125-25-067071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000119312525067071/d660778d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-067071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer